Welcome to the NextPlat Corp Second Quarter 2026 Earnings Call. Certain statements made during this conference call constitute forward-looking statements. These statements include the capabilities and success of the company's business and any of its products, services, or solutions. The words believe, forecast, project, intend, expect, plan, should, would, and similar expressions in all statements which are not historical facts are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, any of which could cause the company to not achieve some or all of its goals, or the company's previously reported actual results, performance, finance or operating, including those expressed or implied by such forward-looking statements. More detailed information about the company and the risk factors that may affect the realization of forward-looking statements is set forth in the company's filings with the Securities and Exchange Commission, the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. The company assumes no and hereby disclaims any obligation to update the forward-looking statements made during this conference call. Joining us on the call today are David Phipps, Chief Executive Officer, Amanda Ferrio, Chief Financial Officer, and Birute Norkute, Vice President of Healthcare Operations. I'll now turn the call over to David Phipps for his opening remarks. Good morning, and welcome to NextPlat's second quarter 2026 results conference call. Thank you for joining us. On today's call, we will discuss our significantly improved second quarter results and highlight the many positive developments occurring in the business. In addition to discussing results of the quarter, we will also elaborate on key elements of our business strategy and focus areas so you can gain a better understanding of where we are heading and our current expectations regarding our future growth and profitability. As is customary, I will begin today's call by briefly recapping the results of the second quarter, then turn the call over to Birute Norkute, our Vice President of Healthcare Operations, to discuss that segment in more detail, and then turn the call over to Amanda Ferrio, our Chief Financial Officer, to review our financial results. Following that, I will make closing remarks and then conclude the conference call by responding to questions that were submitted by our shareholders. Our second quarter results provide clear evidence that the turnaround initiated over the past year is delivering meaningful results. Strong sequential growth in our e-commerce and contracted healthcare services, particularly 340B, helped drive our consolidated gross margin to a record level of approximately 40%, while our net loss was virtually eliminated. We are extremely encouraged by this momentum and believe the positive trends across our markets position us to accelerate growth, achieve sustainable profitability, and create significant long-term shareholder value. Importantly, our progress extends well beyond cost reductions. We are successfully unlocking the value of our operations, particularly by using our community pharmacies as local hubs for higher margin 340B, long-term care, and institutional healthcare services. Our planned acquisition near Pensacola will further advance the strategy, strengthening a differentiated business model that sets us apart from traditional national pharmacy chains and creates exciting opportunities for continued expansion. At this point, I'd like to now review our business and provide some additional insights, which I believe will be helpful for investors in measuring our progress. In our healthcare segment, we are pleased to report the following improvements in operations during the second quarter. As a result of our concerted efforts to invest in our higher margin contracted healthcare service businesses, during the second quarter, we continued to see accelerating growth in prescription volumes from our higher margin 340B and government healthcare customers. Contracted pharmacy revenue increased 136% to approximately $2.2 million, driven by medication fulfillment contracts secured in late 2025 and early 2026. On a sequential basis, contracted pharmacy revenue increased approximately 20% from the first quarter of 2026, supported by ongoing business development activity and the addition of multiple new contracted clients. As has been the trend since last year-over-year total pharmacy prescription revenue was down as anticipated, primarily reflecting lower pay and reimbursement rates and payer mix, something Amanda will comment on shortly. The strong growth in contracted pharmacy revenue is offsetting these expected headwinds. As we noted in our CEO update announcement and earnings press release, momentum in this segment is building as we set another record, adding six new 340B contracts in Q2, beating the first quarter record of five new contracts. We expect continued growth throughout the remainder of the year as revenue from the five new covered entities secured in the first quarter and new entities secured in Q2 begin contributing to our results later in the current quarter and more fully in the fourth quarter. In terms of the retail pharmacy business, as I noted earlier, while there continue to be challenges here, we believe our diversified business model built around well-managed community pharmacies, combined with the addition of our contracted services offerings, will allow us to profitably grow the business. As such, growing contracted services revenue, as well as the additional pharmacy revenue from our acquisition, are expected to contribute to meaningful sequential and year-over-year top-line healthcare revenue growth starting in the third quarter and early fourth quarter. Finally, as we indicated last quarter, we are actively expanding the scale and scope of our business through two key pathways. First, we are preparing for the launch of a new online e-commerce healthcare website, which will feature an array of popular prescription medications such as GLP-1s and over-the-counter products, including our Florida Sunshine brand of premium vitamins and supplements. This new healthcare e-commerce website will allow us to leverage our relationships with current and potential customers as part of our go-to-market plans. The new site is expected to go live this quarter. Second, we are actively working on additional growth initiatives at our Pharmco subsidiary, which we believe will quickly add more scale to its operations, both through potential acquisitions as well as relocating one of our pharmacies to a new location not currently serviced by our existing pharmacies. We expect to announce developments on these efforts shortly. In our e-commerce segment, here are the most recent highlights. The global demand for satellite-based connectivity products continues to be strong, and during Q2, we generated sales from customers in 115 countries and produced record levels of high-margin recurring airtime contract revenue. Looking at the demand we are seeing, there is particular strength in the government and military sector in Europe, where we are receiving increasing orders for satellite-enabled Internet of Things products offered by partners such as Iridium and Globalstar, as well as Iridium push-to-talk devices under contract with the UK Government department. Over $1.75 million in sales to government sector customers in the first half of 2026 continues to support sequential growth in this segment. At this point, I would now like to turn the call over to Birute for her update. Thank you, David. In our healthcare business, second quarter results reflect the operational improvements in business development investments made over the past several quarters, and a deliberate shift in the composition of our volume toward higher-value contracted services. We filled approximately 96,000 prescriptions during the quarter, compared with approximately 91,000 in the prior year period. Within that total, 340B prescriptions grew to approximately 7,500, an increase of more than 33% year-over-year. Retail prescription revenue declined year-over-year. This was anticipated and primarily reflects lower payer reimbursement rates and payer mix. Pressures affected retail pharmacy broadly across the industry. Growth in our contracted and 340B businesses helped offset these headwinds. Turning to profitability. The healthcare gross margins was about approximately 46% in the second quarter, compared with 39% in the first quarter of 2026, and 20% in the second quarter of 2025. Healthcare gross profit increased to approximately $3.6 million, from approximately $1.8 million in the prior year period, reflecting greater profitability on a lower revenue base. Contracted and 340B services represent approximately 61% of total healthcare gross profit, compared with approximately 52% a year ago. Our expanded sales, account management, and business development teams continued to generate traction, particularly within our 340B vertical. We secured six new contracted covered entities during the second quarter, following five in the first quarter, each a quarterly record. These agreements typically require approximately 90 days to onboard before entities begin referring prescriptions for fulfillment. We expect revenue from the five entities secured in the first quarter to begin contributing late in the current quarter, with the second quarter cohort contributing more fully in the fourth quarter. On our footprint. Subsequent to quarter end, we announced an agreement to acquire a profitable pharmacy operation in Pensacola area of the Northwest Florida, a market we do not currently serve. The transaction is expected to close by the fourth quarter, subject to customary closing conditions, and will be funded from cash on hand. Beyond extending our geographic reach, this acquisition provides a licensed physical platform through which we can introduce the higher value services we have built, 340B support, contracted medication fulfillment, and provider relationships. That is the model we intend to apply as we evaluate additional markets and adjacent service lines. One note on the margin profile. Our contracted business remains concentrated among a limited number of entities, and mix in any given quarter can move margin in either direction. We are focused on broadening that base as new covered entities onboard. Our operating priorities for the second half are straightforward. Onboarding the 11 covered entities secured year to date to full referral volume, closing and integrating the Pensacola operation, and continuing to optimize our Florida footprint. We are pleased with the more efficient and scalable healthcare platform we have built, and we remain focused on growing this business deliberately, delivering value to our customers, our patients, and the communities we serve. That concludes my remarks. Back to you, David. Thank you, Birute. At this point, I will turn the call over to Amanda to discuss our financial results for the quarter ended June 30th, 2026. Thank you, David. Good morning, everyone. The second quarter of 2026 reflects the impact of the turnaround work we began last year and continues the positive sequential trends we established late in 2025. These initiatives implemented throughout 2025 are now translating into measurable improvements in margins, operating efficiency, and overall financial performance. Unless I note otherwise, the figures I will discuss are rounded. Precise amounts are in the press release and the soon-to-be-filed Form 10-Q. For the second quarter of 2026, total net revenues were $11.9 million, compared to $13.2 million in the prior year period and $9.9 million in the first quarter of 2026, a sequential improvement of more than 20%. Year-over-year revenue comparisons continue to reflect the operational restructuring and the evolving reimbursement dynamics within our healthcare business. As we have said previously, we believe the more important trend is the sequential improvement in revenue, margins, and operating leverage. Looking to the third and fourth quarters, we believe that in addition to continued sequential improvement, year-over-year comparisons should become more favorable. Within healthcare operations, second quarter net revenues were $7.8 million, compared to $9.1 million in the second quarter of 2025. The composition of that revenue continued to shift towards higher value, more sustainable streams, specifically 340B contract services and medication fulfillment services. Pharmacy contract revenue increased to $2.2 million, compared with $0.9 million in the prior year period, an increase of 136%. Roughly $0.7 million of that increase came from 340B contract services, primarily expanded volume under existing covered entity relationships, and $0.6 million came from the medication fulfillment contracts we secured late in 2025. On a sequential basis, pharmacy contract revenue increased 20% from the first quarter. Pharmacy prescription revenues net were $5.6 million, compared with $8.2 million in the prior year period. That year-over-year decrease reflects $1.6 million of lower reimbursement rates and $1 million of lower prescription volume, consistent with the changes in payer reimbursement and payer mix we have discussed. The more important point is what is happening underneath. Sequentially, prescription revenue increased 16% from the first quarter, and gross margin on that business improved to 25% from 11% a year ago. That improvement reflects higher gross profit per prescription, a shift in dispensing mix, continued margin discipline, and the effect of the Medicare Maximum Fair Price program that took effect in January. Turning to e-commerce operations, this segment continued to be a steady performer and an important contributor to the business. Revenue was $4.1 million, essentially flat with the prior year period and up 27% sequentially from $3.2 million in the first quarter. Gross margin in this segment was 27%, compared with 26% a year ago. Demand remained solid across satellite-based connectivity and IoT products, and we continue to believe this segment is well-positioned to provide consistent cash flow generation and long-term growth opportunities. Consolidated gross profit for the quarter was $4.7 million, an increase of 63% compared to $2.9 million in the prior year period and $3.4 million in the first quarter. Consolidated gross margin improved to 40%, compared with 22% in the second quarter of 2025, an expansion of roughly 18 percentage points, and up from 35% in the first quarter of 2026. Within healthcare operations, gross margin was 46%, compared to 20% a year ago. This is the strongest quarterly gross margin performance in the company's history and reflects the direct benefit of our strategy to improve revenue quality and overall operating efficiency. Total operating expenses were $4.8 million, compared with $4.7 million in the second quarter of 2025, an increase of about 2%. That modest increase is entirely attributable to professional fees included within selling, general, and administrative expenses, which rose approximately $0.5 million year-over-year. Every other operating expense line declined or remained flat. Excluding the increase in professional fees, our operating expense base declined year-over-year, and we would expect the elevated professional fee level to moderate as the year progresses. The combined improvement in gross profit and operating discipline brought us to near breakeven. Operating loss for the second quarter was $127,000, compared with $1.8 million in the prior year period, a reduction of 93%, and compared with an operating loss of $1.1 million in the first quarter of 2026. Net loss attributable to common stockholders was $144,000 or $0.05 per share, compared with a net loss of $1.8 million or $0.69 per share in the second quarter of 2025. From a segment perspective, both operating segments were profitable in the quarter. Healthcare operations generated segment operating income of $1 million, compared with a segment operating loss of $1.1 million in the prior year period and a segment operating income of $24,000 in the first quarter of 2026. E-commerce operations generated segment operating income of $200,000, compared with $88,000 in the prior year period, and a segment operating loss of $84,000 in the first quarter. We ended the quarter with $11.9 million in cash, an increase of $0.9 million from March 31st, and working capital of $14.2 million. For the first six months of the year, cash used in operating activities was $1.5 million, compared with $3.1 million in the same period last year. We continue to maintain a healthy liquidity position and a conservative balance sheet with no meaningful debt. In July, we announced an agreement to acquire a community pharmacy near Pensacola, Florida for $1.5 million in cash. That transaction is targeted to close by the end of the third quarter and remains subject to customary closing conditions, including completion of due diligence and negotiation of a lease for the premises. Assuming it closes on that timeline, we would expect our third quarter cash balance to reflect that outflow. I would also note that we have not sold any shares under the at-the-market program we established in May. It remains available to provide financial flexibility to support growth initiatives, including potential joint ventures or acquisitions, but we have no specific plans for its use at this time. Looking ahead, our priorities for the remainder of 2026 remain centered on continuing to expand contract-based healthcare and fulfillment services, sustaining gross margins and improving operating leverage, maintaining disciplined expense management, including corporate overhead, supporting growth organically through recurring and contract-based revenue streams, while also evaluating strategic opportunities such as possible joint ventures or acquisitions, improving cash flow performance, and positioning the company for sustained profitability. Based on the improved fundamentals in the business and the anticipated contribution from new contracted services and healthcare operations, we believe the sequential financial improvements we are seeing are sustainable. If current trends continue, we expect to reach bottom-line profitability beginning in the third quarter and to sustain it into 2027. I would note two things about that expectation. The third quarter will absorb transaction and integration costs related to the pharmacy acquisition, and this is a forward-looking statement subject to the risks and uncertainties described in our filings. I encourage you to review our financial statements and disclosures in our quarterly report on Form 10-Q for additional detail. That concludes my remarks. Back to you, David. Thank you, Amanda. Before we turn to investor questions, I would like to make some closing remarks and provide some insights into what we see over the remainder of 2026 and beyond. As I indicated earlier, as a team, we are pleased with the improvements made by the company over the past year. The progress we have made has clearly created a robust platform for steady sequential growth and profitability. Furthermore, supported by a strong financial foundation, we now have the increased ability to focus our attention on the future, investing in key areas that will support growth and profitability. In healthcare, we will continue to capitalize on the many opportunities we see for growth, both organically and through accretive acquisitions. By combining retail, specialty, institutional, 340B, and government services through a single pharmacy operation, we can support multiple patient populations and healthcare partners. This diversified model reduces reliance on any one customer channel and creates several avenues for sustainable long-term growth, providing us with the ability to expand our footprint at a time when the mass retail chains are increasingly facing significant challenges. In e-commerce, through initiatives such as our new online healthcare marketplace and supported by continued strong global demand for satellite-based connectivity products, we are creating an expanded platform capable of delivering products to millions of consumers, no matter where they are. For our investors, we remain committed to delivering on the value we see in the business. With our turnaround largely complete, we are positioned to drive top and bottom-line results, which we believe will create sustainable shareholder value over the short and long term. There is always more work to be done, but our successful turnaround efforts provide us with increased confidence that we are achieving our goals and creating sustainable value for all of our stakeholders. We wish to thank our shareholders for their continued support. At this point, we can now conduct the Q&A portion of today's call. We have again asked investors and shareholders to submit their questions in advance, and we would like to thank all of you who did. Question number one, can you comment on additional acquisitions in the pharmacy space? Are you looking beyond Florida? How would you fund future acquisitions? Would you have to dilute current shareholders? At this point in time, we see many advantages to concentrating our brick-and-mortar focus on Florida due to attractive population demographics and our well-established infrastructure. We are actively exploring additional acquisitions in Florida, looking for transactions which meet our specific requirements, namely in markets not saturated by the larger chains, established locations with solid customer bases, and importantly, attractive financials, specifically profitable operations. To be clear, we are approaching future acquisitions in a very conservative and prudent manner, specifically as it relates to their ability to add accretively to our business, their margins, cash flow, and profitability. Because of our improved operating results, we have significant flexibility on how we could fund a transaction. We could consider using a combination of restricted shares, earn-outs, cash, or even bank lines of credit, which would allow us to capture value without simply diluting our shareholders. Question number two, will AI play a role in the company's operations? If so, how will it affect the company's business? AI is becoming increasingly important to our growth strategy and operating capabilities. It enables us to identify and respond to trends across our e-commerce and healthcare businesses more quickly, while also helping us efficiently process and analyze the growing volumes of patient data generated as our healthcare operations expand. AI is also a core component of ClearMetrX, our proprietary healthcare data analytics and reporting platform, which was recently deployed internally and with customers. On the e-commerce side, we have developed several new systems internally which automate tasks and improve efficiency using AI. Question number three, does the company have any update on the status of the ongoing lawsuit? As of today, there is no update beyond what we have already disclosed in our previously filed periodic reports. Our Form 10-Q for the second quarter will be filed shortly and contains our current disclosure on this matter, so I would refer you to there and to our prior filings. This remains in the hands of counsel and our insurance company. We remain committed to resolving it as quickly as possible while protecting the long-term interests of our shareholders. That was the final question that we received from investors. Thank you all again for submitting them. Please remember that you can submit your questions on our investor relations email, which is investors@nextplat.com, or with our IR contact listed on our press releases, Michael Glickman at mike@mwgco.net. That concludes our earnings conference call. We look forward to continuing to share with you our progress in the weeks and months ahead. Have a nice rest of your day. Ladies and gentlemen, thank you for your participation. This does conclude today's call.